Advertisement

Endocrinologic Issues

  • Mimi I. Hu
  • Camilo Jimenez
  • Naifa L. Busaidy
  • Mouhammed Amir Habra
Chapter
Part of the MD Anderson Cancer Care Series book series (MDCCS)

Abstract

This chapter outlines the important and common late-onset, long-term endocrine disorders that occur as a consequence of cancer therapy in survivors: bone metabolism disorders, metabolic (i.e., glucose and lipid) disorders, thyroid neoplasia and dysfunction, hypothalamic-pituitary dysfunction, adrenal dysfunction, and gonadal system disorders. Strategies for evaluating and managing these effects are included.

Keywords

Bone Mineral Density Bone Loss Cancer Survivor Androgen Deprivation Therapy Adrenal Insufficiency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Suggested Readings

  1. Agha A, Sherlock M, Brennan S, et al. Hypothalamic-pituitary dysfunction after irradiation of nonpituitary brain tumors in adults. J Clin Endocrinol Metab 2005;90:6355–6360.PubMedCrossRefGoogle Scholar
  2. Allolio B, Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006;91:2027–2037.PubMedCrossRefGoogle Scholar
  3. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802–1810.PubMedCrossRefGoogle Scholar
  4. Berruti A, Gorzegno G, Vitetta G, et al. Hypertriglyceridemia during long-term interferon-alpha therapy: efficacy of diet and gemfibrosil treatment. A case report. Tumori 1992;78:353–355.PubMedGoogle Scholar
  5. Bokemeyer C, Berger CC, Kuczyk MA, et al. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996;14:2923–2932.PubMedGoogle Scholar
  6. Boonen S, Adachi JD, Man Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2011;96:1727–1736.PubMedCrossRefGoogle Scholar
  7. Borson-Chazot F, Brue T. Pituitary deficiency after brain radiation therapy. Ann Endocrinol (Paris) 2006;67:303–309.CrossRefGoogle Scholar
  8. Brougham MF, Kelnar CJ, Wallace WH. The late endocrine effects of childhood cancer treatment. Pediatr Rehabil 2002;5:191–201.PubMedGoogle Scholar
  9. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990;76:1704–1709.PubMedGoogle Scholar
  10. Chan WB, Cockram CS. Panhypopituitarism in association with interferon-alpha treatment. Singapore Med J 2004;45:93–94.PubMedGoogle Scholar
  11. Charak BS, Gupta R, Mandrekar P, et al. Testicular dysfunction after cyclophosphamide-vincristine-procarbazine-prednisolone chemotherapy for advanced Hodgkin’s disease. A long-term follow-up study. Cancer 1990;65:1903–1906.PubMedCrossRefGoogle Scholar
  12. Chen Z, Maricic M, Bassford TL, et al. Fracture risk among breast cancer survivors: results from the Women’s Health Initiative Observational Study. Arch Intern Med 2005;165:552–558.PubMedCrossRefGoogle Scholar
  13. Choo YC, Chan SY, Wong LC, et al. Ovarian dysfunction in patients with gestational trophoblastic neoplasia treated with short intensive courses of etoposide (VP-16-213). Cancer 1985;55:2348–2352.PubMedCrossRefGoogle Scholar
  14. Cohen LE. Endocrine late effects of cancer treatment. Endocrinol Metab Clin North Am 2005;34:769–789.PubMedCrossRefGoogle Scholar
  15. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007;8:119–127.PubMedCrossRefGoogle Scholar
  16. Concha LB, Carlson HE, Heimann A, et al. Interferon-induced hypopituitarism. Am J Med 2003;114:161–163.PubMedCrossRefGoogle Scholar
  17. Constine LS, Rubin P, Woolf PD, et al. Hyperprolactinemia and hypothyroidism following cytotoxic therapy for central nervous system malignancies. J Clin Oncol 1987;5:1841–1851.PubMedGoogle Scholar
  18. Constine LS, Woolf PD, Cann D, et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 1993;328:87–94.PubMedCrossRefGoogle Scholar
  19. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997;157:439–444.PubMedCrossRefGoogle Scholar
  20. Delaney V, de Pertuz Y, Nixon D, et al. Indomethacin in streptozocin-induced nephrogenic diabetes insipidus. Am J Kidney Dis 1987;9:79–83.PubMedCrossRefGoogle Scholar
  21. Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006;145:660–664.PubMedCrossRefGoogle Scholar
  22. Dillard T, Yedinak CG, Alumkal J, et al. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010;13:29–38.PubMedCrossRefGoogle Scholar
  23. Dora JM, Leie MA, Netto B, et al. Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients. Eur J Endocrinol 2008;158:771–772.PubMedCrossRefGoogle Scholar
  24. Dorfinger K, Niederle B, Vierhapper H, et al. Suramin and the human adrenocortex: results of experimental and clinical studies. Surgery 1991;110:1100–1105.PubMedGoogle Scholar
  25. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001a;19:2456–2471.PubMedGoogle Scholar
  26. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001b;137:581–593.PubMedGoogle Scholar
  27. Eckardt K, May C, Koenen M, et al. IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia 2007;50:2534–2543.PubMedCrossRefGoogle Scholar
  28. Ellis GK, Bone HG, Chlebowski R, et al. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat 2009;118:81–87.PubMedCrossRefGoogle Scholar
  29. Eriksson S, Eriksson A, Stege R, et al. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 1995;57:97–99.PubMedCrossRefGoogle Scholar
  30. Ezdinli EZ, Stutzman L. Chlorambucil therapy for lymphomas and chronic lymphocytic leukemia. JAMA 1965;191:444–450.Google Scholar
  31. Faris JE, Moore AF, Daniels GH. Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report. Thyroid 2007;17:1147–1149.PubMedCrossRefGoogle Scholar
  32. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813–822.PubMedCrossRefPubMedCentralGoogle Scholar
  33. Freckman HA, Fry HL, Mendez FL, et al. Chlorambucil-prednisolone therapy for disseminated breast carcinoma. JAMA 1964;189:23–26.PubMedGoogle Scholar
  34. Fujiwara H, Umeda Y, Yonekura S. Cerebellar infarction with hypertriglyceridemia during all-trans retinoic acid therapy for acute promyelocytic leukemia. Leukemia 1995;9:1602–1603.PubMedGoogle Scholar
  35. Gillette PC, Hill LL, Starling KA, et al. Transient diabetes mellitus secondary to L-asparaginase therapy in acute leukemia. J Pediatr 1972;81:109–111.PubMedCrossRefGoogle Scholar
  36. Gleeson HK, Shalet SM. The impact of cancer therapy on the endocrine system in survivors of childhood brain tumours. Endocr Relat Cancer 2004;11:589–602.PubMedCrossRefGoogle Scholar
  37. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008;9:840–849.PubMedCrossRefGoogle Scholar
  38. Gralow JR, Biermann JS, Farooki A, et al. NCCN task force report: bone health in cancer care. J Natl Compr Canc Netw 2009;7:S1–S35.PubMedPubMedCentralGoogle Scholar
  39. Greenspan SL, Brufsky A, Lembersky BC, et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 2008;26:2644–2652.PubMedCrossRefPubMedCentralGoogle Scholar
  40. Grossmann M, Premaratne E, Desai J, et al. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) 2008;69:669–672.CrossRefGoogle Scholar
  41. Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst 2011;103:1572–1587.PubMedCrossRefPubMedCentralGoogle Scholar
  42. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009;52:1732–1744.PubMedCrossRefPubMedCentralGoogle Scholar
  43. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125–1132.PubMedCrossRefGoogle Scholar
  44. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009;12:2499–2506.CrossRefGoogle Scholar
  45. Howard GC. Fertility following cancer therapy. Clin Oncol (R Coll Radiol) 1991;3:283–287.CrossRefGoogle Scholar
  46. Howard SC, Pui CH. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev 2002;16:225–243.PubMedCrossRefGoogle Scholar
  47. Howell A. The ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) trial: a step forward in the treatment of early breast cancer. Rev Recent Clin Trials 2006;1:207–215.PubMedCrossRefGoogle Scholar
  48. Howell SJ, Shalet SM. Effect of cancer therapy on pituitary-testicular axis. Int J Androl 2002;25:269–276.PubMedCrossRefGoogle Scholar
  49. Hu MI, Gagel RF, Jimenez C. Bone loss in patients with breast or prostate cancer. Curr Osteoporosis Rep 2007;5:170–178.CrossRefGoogle Scholar
  50. Ishii K, Aoki Y, Sasaki M, et al. Syndrome of inappropriate secretion of antidiuretic hormone induced by intraarterial cisplatin chemotherapy. Gynecol Oncol 2002;87:150–151.PubMedCrossRefGoogle Scholar
  51. Janssens K, ten Dijke P, Janssens S, et al. Transforming growth factor-beta1 to the bone. Endocr Rev 2005;26:743–774.PubMedCrossRefGoogle Scholar
  52. Jeruss JS, Woodruff TK. Preservation of fertility in patients with cancer. N Engl J Med 2009;360:902–911.PubMedCrossRefPubMedCentralGoogle Scholar
  53. Kanamaru A, Takemoto Y, Tanimoto M, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood 1995;85:1202–1206.PubMedGoogle Scholar
  54. Karasek M, Pawlikowski M, Lewinski A. [Hyperprolactinemia: causes, diagnosis, and treatment]. Endokrynol Pol 2006;57:656–662.PubMedGoogle Scholar
  55. Kusuki M, Iguchi H, Nakamura A, et al. The syndrome of inappropriate antidiuretic hormone secretion associated with chemotherapy for hypopharyngeal cancer. Acta Otolaryngol Suppl 2004:74–77.Google Scholar
  56. Land VJ, Sutow WW, Fernbach DJ, et al. Toxicity of L-asparginase in children with advanced leukemia. Cancer 1972;30:339–347.PubMedCrossRefGoogle Scholar
  57. Langsenlehner T, Stiegler C, Quehenberger F, et al. Long-term follow-up of patients with pituitary macroadenomas after postoperative radiation therapy: analysis of tumor control and functional outcome. Strahlenther Onkol 2007;183:241–247.PubMedCrossRefGoogle Scholar
  58. Lushbaugh CC, Casarett GW. The effects of gonadal irradiation in clinical radiation therapy: a review. Cancer 1976;37:1111–1125.PubMedCrossRefGoogle Scholar
  59. Maillefert JF, Sibilia J, Michel F, et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999;161:1219–1222.PubMedCrossRefGoogle Scholar
  60. Mannavola D, Coco P, Vannucchi G, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007;92:3531–3534.PubMedCrossRefGoogle Scholar
  61. Marsden J. Hyperlipidaemia due to isotretinoin and etretinate: possible mechanisms and consequences. Br J Dermatol 1986;114:401–407.PubMedCrossRefGoogle Scholar
  62. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001;7:535–543.PubMedCrossRefGoogle Scholar
  63. Melton LJ 3rd, Alothman KI, Khosla S, et al. Fracture risk following bilateral orchiectomy. J Urol 2003;169:1747–1750.PubMedCrossRefGoogle Scholar
  64. Miyake H, Kurahashi T, Yamanaka K, et al. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. Urol Oncol 2009;5:515–519.Google Scholar
  65. Murray-Lyon IM, Cassar J, Coulson R, et al. Further studies on streptozotocin therapy for a multiple-hormone-producing islet cell carcinoma. Gut 1971;12:717–720.PubMedCrossRefPubMedCentralGoogle Scholar
  66. Negro A, Regolisti G, Perazzoli F, et al. Ifosfamide-induced renal Fanconi syndrome with associated nephrogenic diabetes insipidus in an adult patient. Nephrol Dial Transplant 1998;13:1547–1549.PubMedCrossRefGoogle Scholar
  67. Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283–291.PubMedCrossRefGoogle Scholar
  68. Olshan JS, Gubernick J, Packer RJ, et al. The effects of adjuvant chemotherapy on growth in children with medulloblastoma. Cancer 1992;70:2013–2017.PubMedCrossRefGoogle Scholar
  69. Otsuka F, Hayashi Y, Ogura T, et al. Syndrome of inappropriate secretion of antidiuretic hormone following intra-thoracic cisplatin. Intern Med 1996;35:290–294.PubMedCrossRefGoogle Scholar
  70. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006;24:3629–3635.PubMedCrossRefGoogle Scholar
  71. Petersen PM, Hansen SW, Giwercman A, et al. Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. Ann Oncol 1994;5:355–358.PubMedGoogle Scholar
  72. Rappaport R, Brauner R, Czernichow P, et al. Effect of hypothalamic and pituitary irradiation on pubertal development in children with cranial tumors. J Clin Endocrinol Metab 1982;54:1164–1168.PubMedCrossRefGoogle Scholar
  73. Robinson C, Jeffries RC, Walsh GC. Inappropriate ADH secretion caused by oat cell carcinoma and relieved by lung resection. Thorax 1980;35:635–637.PubMedCrossRefPubMedCentralGoogle Scholar
  74. Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995;141:259–277.PubMedCrossRefGoogle Scholar
  75. Rose SR, Schreiber RE, Kearney NS, et al. Hypothalamic dysfunction after chemotherapy. J Pediatr Endocrinol Metab 2004;17:55–66.PubMedCrossRefGoogle Scholar
  76. Rossi R, Godde A, Kleinebrand A, et al. Concentrating capacity in ifosfamide-induced severe renal dysfunction. Ren Fail 1995;17:551–557.PubMedCrossRefGoogle Scholar
  77. Smalley RV, Wall RL. Two cases of busulfan toxicity. Ann Intern Med 1966;64:154–164.PubMedCrossRefGoogle Scholar
  78. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745–755.PubMedCrossRefPubMedCentralGoogle Scholar
  79. Smith MR, McGovern FJ, Fallon MA, et al. Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 2001a;91:2238–2245.PubMedCrossRefGoogle Scholar
  80. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001b;345:948–955.PubMedCrossRefGoogle Scholar
  81. Sorensen JB, Andersen MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med 1995;238:97–110.PubMedCrossRefGoogle Scholar
  82. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132–5129.PubMedCrossRefGoogle Scholar
  83. Vahlquist C. Effects of retinoids on lipoprotein metabolism. Curr Probl Dermatol 1991;20:73–78.PubMedGoogle Scholar
  84. van Ditzhuijsen CI, van de Weijer R, Haak HR. Adrenocortical carcinoma. Neth J Med 2007;65:55–60.PubMedGoogle Scholar
  85. Vassilopoulou-Sellin R, Samaan NA. Mitotane administration: an unusual cause of hypercholesterolemia. Horm Metab Res 1991;23:619–620.PubMedCrossRefGoogle Scholar
  86. Vehmanen L, Elomaa I, Blomqvist C, et al. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006;24:675–680.PubMedCrossRefGoogle Scholar
  87. Vialettes B, Guillerand MA, Viens P, et al. Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies. Acta Endocrinol (Copenh) 1993;129:31–38.Google Scholar
  88. Ward HN, Konikov N, Reinhard EH. Cytologic dysplasia occurring after busulfan (myleran) therapy. A syndrome resembling adrenocortical insufficiency and atrophic bronchitis. Ann Intern Med 1965;63:654–660.PubMedCrossRefGoogle Scholar
  89. Weinstein D, Simon M, Yehezkel E, et al. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 2009;25:41–49.PubMedCrossRefGoogle Scholar
  90. Wong E, Rosen LS, Mulay M, et al. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid 2007;17:351–355.PubMedCrossRefGoogle Scholar
  91. Wong LC, Choo YC, Ma HK. Primary oral etoposide therapy in gestational trophoblastic disease. An update. Cancer 1986;58:14–17.PubMedCrossRefGoogle Scholar

Copyright information

© The University of Texas M. D. Anderson Cancer Center 2015

Authors and Affiliations

  • Mimi I. Hu
    • 1
  • Camilo Jimenez
    • 1
  • Naifa L. Busaidy
    • 1
  • Mouhammed Amir Habra
    • 1
  1. 1.Department of Endocrine Neoplasia and Hormonal DisordersThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations